FindTrial
Sign In

Comparison of MSI detection between next-generation sequencing and PCR in different tumors

Comparison of MSI detection between TSO500, 2B3D panel and other detection technologies in different tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052649
Enrollment
Unknown
Registered
2021-11-03
Start date
2021-12-30
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, stomach cancer, endometrial cancer, etc.

Interventions

Case series:None

Sponsors

Fujian Medical University Cancer Hospital/Fujian Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Colorectal cancer, gastric cancer, endometrial cancer and other tumor tissue samples; 2. The tumor cell content is more than 20%; 3. Normal control; 4. The amount of DNA meets the experimental needs.

Exclusion criteria

Exclusion criteria: 1. More than 2 years; 2. Pathological evaluation not clear; 3. Small Pathological samples such as fine needle samples.

Design outcomes

Primary

MeasureTime frame
Concordance;negative predictive value;—

Secondary

MeasureTime frame
positive predictive value;—

Countries

China

Contacts

Public ContactChen Gang

Fujian Medical University Cancer Hospital/Fujian Cancer Hospital

naichengang@126.com+86 591 83660063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026